GE HealthCare agrees $945m acquisition of SOFIE Biosciences to expand US radiopharma network
GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million, expanding its US PET radiopharmaceutical manufacturing and distribution network.
The acquisition adds SOFIE's US radiopharmaceutical infrastructure and rights to the Phase III FAPI-74 pan-cancer imaging radiotracer.
The deal strengthens GE HealthCare's final-mile PET supply capabilities and broadens its position in precision imaging and radiopharmaceuticals.
Field | Content |
Article Type | Deals |
Companies | GE HealthCare; SOFIE Biosciences |
Deal Type | Acquisition |
Transaction Value | $945 million in cash |
Acquired Company | SOFIE Biosciences |
Therapy Areas | Oncology; diagnostic imaging; nuclear medicine |
Technology/Modality | PET radiopharmaceuticals |
Key Asset | FAPI-74 |
Development Stage | Phase III |
Infrastructure | US PET radiopharmaceutical contract manufacturing and distribution network |
What Happened | GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash. |
Why It Matters | The acquisition gives GE HealthCare additional radiopharmaceutical manufacturing and distribution infrastructure in the US while adding a late-stage pan-cancer imaging asset. |
Supporting Context | SOFIE's network supports the final-mile supply of short-lived PET radiopharmaceuticals, an important operational requirement for nuclear medicine imaging. |
Strategic Rationale | GE HealthCare is strengthening its radiopharmaceutical platform and expanding its ability to manufacture and distribute F18 PET products closer to imaging centres. |
Potential Impact | The transaction could broaden access to PET imaging agents and strengthen GE HealthCare's position in precision oncology imaging. |
Key Takeaway | GE HealthCare is acquiring SOFIE Biosciences for $945 million to expand its US radiopharmaceutical network and add FAPI-74. |
What to Watch | Transaction completion, integration of SOFIE's network and Phase III development and potential commercialisation of FAPI-74. |
Primary Source | GE HealthCare |
Relevant Date | 5 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti